Help us: Donate
Follow us on:

OneSkin Has Released a Senotherapeutic Skin Cream

Preprint data is now available, but only for human skin models and skin biopsies.


If there is one thing about aging research that is almost sure to grab public attention, it is something that has a visible effect. A new product on the market that claims to reduce senescent cells in aged skin could achieve that, assuming that the pending human study is successful.

OneSkin recently released OS-01, a cosmetic skin care product that claims to reduce the activity of senescent cells according to typical cellular senescence biomarkers, such as p16 expression and senescence-associated β-galactosidase.

We would normally be skeptical about such an “anti-aging” product, given that the marketplace is filled with hucksters, grifters, and people looking to make a quick buck from people lacking the scientific knowledge to spot a scam. However, the data presented in this preprint paper from the researchers behind OneSkin is, if nothing else, worth taking a look at.

The compound of interest in OS-01 is peptide 14, which may or may not have senolytic properties. The data presented in the preprint is suggestive of the compound being a senomorphic, meaning that it inhibits or otherwise changes senescent cell secretions, rather than it being an outright senolytic.

Of note, the researchers compared their peptide with rapamycin and noted that peptide 14 promoted the maintenance of the overall structure in their 3D skin models, while rapamycin caused a detrimental effect in overall skin structure, including a thinner and more disorganized epidermis. Rapamycin has a known delaying effect on skin cell senescence and so makes for a good comparison.

It may be the case that the peptide could be somehow preventing some cells from becoming senescent or at least delaying them long enough for the body to partially clear the senescent cell backlog.

Skin aging has been primarily related to aesthetics and beauty. Therefore, interventions have focused on reestablishing skin appearance, but not necessarily skin health, function, and resilience. Recently, cellular senescence was shown to play a role in age-related skin function deterioration and influence organismal health and, potentially, longevity. In the present study, a two-step screening was performed to identify peptides capable of reducing cellular senescence in human dermal fibroblasts (HDF) from Hutchinson-Gilford Progeria (HGPS) patients. From the top four peptides of the first round of screening, we built a 764-peptide library using amino acid scanning, of which the second screen led to the identification of peptide 14. Peptide 14 effectively decreased HDF senescence induced by HGPS, chronological aging, ultraviolet-B radiation, and etoposide treatment, without inducing significant cell death, and likely by modulating longevity and senescence pathways. We further validated the effectiveness of peptide 14 using human skin equivalents and skin biopsies, where peptide 14 promoted skin health and reduced senescent cell markers, as well as the biological age of samples, according to the Skin-Specific DNA methylation clock, MolClock. Topical application of peptide 14 outperformed Retinol treatment, the current gold-standard in “anti-aging” skin care. Finally, we determined that peptide 14 is safe for long-term applications and also significantly extends both the lifespan and healthspan of C. elegans worms tested in two independent testings. This highlights the potential for geroprotective applications of the senotherapeutic compounds identified using our screening platform beyond the skin.


How useful this product is remains to be seen, given that there is no published data for its effects in humans. Launching a product prior to conducting a detailed human study that shows efficacy is typical of the cosmetics and supplements industries, and we would urge caution here as with any product.

While there is apparently a pending human study in the works, anyone jumping on the bandwagon now is entering largely uncharted territory. Unless you have plenty of money and are willing to develop a science-based approach to taking and quantifying supplements, it would be prudent to wait for the human study data to arrive.

That said, the researchers behind this seem sincere, and if efficacy in a human study can be demonstrated and skin aging visibly delayed or even reversed, it could encourage increased public interest.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.

All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.

Long-Term Resistance Exercise Increases Autophagy

In a new systemic review published in Autophagy Reports, researchers have demonstrated that exercise plays a role in regulating autophagy,...

A Lasting Rise in Investment in the Longevity Sector

2021 marked one of the biggest years in longevity financing, with 2022 following closely behind, according to a report by...

Mediterranean Diet Might Lower Risk of Dementia

In a large-scale observational study, British scientists have shown that high levels of adherence to the Mediterranean diet might substantially...

Lifespan News – Protein and Muscle

Emmett Short brings up a study talking about how diets with less protein are connected to better muscle maintenance with...

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri – Google AR and Dinorah Delfin – Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
  1. Mathieu Cloutier
    November 17, 2020

    Does anyone produce commercially topical rapamycin based creams or serums? I could not find any.

Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.